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From a biological perspective aging (senescence) appears to be a form of complex
disease syndrome, though this is not the traditional view. This essay aims to
foster a realistic understanding of aging by scrutinizing ideas old and new. The
conceptual division between aging-related diseases and an underlying, non-pathological
aging process underpins various erroneous traditional ideas about aging. Among
biogerontologists, another likely error involves the aspiration to treat the entire aging
process, which recent advances suggest is somewhat utopian. It also risks neglecting a
more modest but realizable goal: to develop preventative treatments that partially protect
against aging.
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Introduction
Is our understanding of aging still in the dark ages? Over the course of the last centuries a gradual
process of enlightenment has taken place in many diﬀerent areas of human understanding, in
which traditional views have been overturned by new knowledge borne of reason and the results
of scientiﬁc investigation. A more realistic view of things, though it can initially cause controversy
by upsetting traditional views and practices, ultimately enables more eﬀective and more ethical
action. Such a process of rationalization has profoundly aﬀected the ﬁeld of medicine, and the
way we view many health-related issues, such as surgery, hygiene, infection, vaccination, abortion,
contraception, homosexuality, and many others.
Yet when it comes to aging this salutary process of rationalization is still in its early stages. Here
a salient example is the widespread and, arguably, false view that aging is distinct from disease
and therefore not appropriate for medical attention – and even something benign and wholesome
(Kass, 1983; Callahan, 1994; Fukuyama, 2002). In this essay I will discuss the distinction drawn
between aging and disease, starting with an account (in the form of a mild parody) of various
traditional but largely false ideas about aging, some of them supported by this misunderstanding. I
will then describe how its elimination yields a clearer picture of the greatest cause of human illness
and death.
Aging vs. Disease: A View from Tradition
According to traditional views, aging is part of the natural order of things that one should not
resist. Although aging seems frightening at ﬁrst, and it is tragic that we all have to die, in the end
it is for the good. From the Judeo–Christian perspective, it is our just punishment for Original
Sin, speciﬁcally that of Eve, who ate the fruit of the tree of knowledge of good and evil –
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cherchez la femme. Aging also serves a function in nature: to weed
out old and worn out individuals thereby freeing up resources for
younger generations. In this way, aging assures the survival of the
species. Thus, one should endure aging and bow out gracefully
with stoicism and dignity in accordance with nature’s wishes.
Conversely, to refuse to accept aging is a sign of weakness of
character, of egotism, like a rich man who tries to avoid paying
his taxes – and, of course, it is folly. There is a right length of life:
3 score and 10 years (i.e., 70); to want more is unseemly, greedy,
and selﬁsh.
Aging is not a disease, but rather a normal and natural process.
Older people do tend to get ill more often and to develop serious
diseases such as cancer and Alzheimer’s disease. Thus, although
aging itself is not a disease, it is associated with an increased
burden of disease. Treating these diseases is the duty of doctors,
and ﬁnding new treatments for them a major priority of medical
research. Such research is worlds apart from the folly of trying to
resist aging.
There are scientists that try to understand the biological basis
of aging. Their priority should be to understand how aging gives
rise to age-related disease in order to ﬁnd ways to protect older
people from late-life illness. The aim of this research is not to
slow aging or increase lifespan, but to increase healthspan, and
to add life to years, not years to life. The ultimate outcome of
biogerontology would be treatments that liberate older people
entirely from pathology, yet allow them to age naturally. This
would allow each of us to then eventually die of pure aging, feeling
well one day, and then dying suddenly the next – perhaps in
our sleep. However, this outcome would not be unproblematic,
as it would cause an increase in the fearful anticipation of
death among the elderly. As expressed by philosopher Leon
Kass: “Would not the fear and loathing of death increase, in
the absence of its antecedent harbingers?” And “Death would
always be untimely, unprepared for, shocking” (Kass, 1988).
Perhaps, therefore, it might be better after all if older people
were left with some age-related disease, some suﬀering, at least
near the end of life, to help ease the prospect of inevitable
death.
Another concern is that some scientists studying aging
pander to that egoistic minority who wish to live longer
than their allotted time. These scientists openly advocate
going beyond looking for treatments for diseases of aging,
and intervening in aging itself. Disturbingly, they have
managed to achieve this using animals models in the
laboratory. Some even claim that aging itself is a disease.
This betrays a contempt for older people, and promotes
their marginalization (Haber, 2004). It also represents
inappropriate medicalization of the elderly – as if they did
not have enough to suﬀer already. Intervening in aging
itself could have horrible consequences, as foreseen by the
ancient Greek myth of Tithonus, the lover of Eos Goddess
of the Dawn. To humor her matrimonial aspirations, Zeus
bestowed immortality upon Tithonus – but not eternal
youth. Consequently, poor Tithonus grew ever more
decrepit but, cruelly, could not die. It would seem that some
scientists studying aging are irresponsible, lacking in human
feeling, and do not know when to stop.
Aging is Disease: An Enlightened
Perspective
The previous section collects together views that I have
encountered many times during my 20 years working as a
biogerontologist, often from members of the public but also
from clinicians, gerontologists, and academics of various other
specialities. In the main these ideas are, I believe, quite false.
A particular source of error is the false dichotomy drawn between
aging and disease.
To lay bare this error, a good place to start is an examination
of the word aging, which can create confusion because it has
several diﬀerent meanings. For one, it can mean an increase in
calendar age; likewise the phrase old age usually means advanced
calendar age (though in the phrase dying of old age it means more
than that). Then it can mean changes that occur with increased
calendar age (age changes). In living organisms age changes
usually refer to those that happen during adulthood, not before.
Age changes in adulthood include those that are beneﬁcial, such
as the hardening of the cuticle in young adult insects, continued
growth in trees, and experience in people. These are benign
maturational changes, and maturity is a virtue. Age changes can
also be deleterious, for example in aging Caenorhabditis elegans,
the worm that I study in my own research, one sees many
pathologies, including breakdown of muscle, intestinal atrophy,
and uterine tumors (Garigan et al., 2002; Herndon et al., 2002;
Luo et al., 2010); in humans, such changes are very numerous
and diverse, ranging from cardiovascular and neurodegenerative
disease to osteoporosis and cataracts. Such deteriorative changes
exemplify senescence which, as deﬁned by Alex Comfort, results
in “a decrease in viability and an increase in vulnerability” and “an
increasing probability of death with increasing chronological age”
(Comfort, 1979). Like other nouns with the suﬃx –escence, which
can indicate either a state, or a process of becoming, senescence
can mean either the state of senescence, or the process of
becoming senescent (c.f. obsolescence). When biogerontologists
speak of aging they usually mean senescence (though not when
speaking of successful or healthy aging). Thus, the fallacy that is
the focus of this essay is, more precisely, the senescence-disease
false dichotomy.
Is senescence a disease? The very word senescence, denoting
deterioration leading to death, certainly carries that implication.
To explore this, the philosopher Arthur Caplan asked two further
questions: Does aging have a purpose? And: Is it distinct from
pathology? (Caplan, 1992, 2005).
If senescence is an evolutionary adaptation, this would to some
extent support the idea that aging is non-pathological. But this
reasoning would also involve a fallacious appeal to nature, a false
equation of human evolutionary ﬁtness with well being. If human
aging did in fact evolve to beneﬁt the species by ridding it of
worn out elderly people, this should not deter us from looking
for treatments for Alzheimer’s disease and cancer.
However, as Caplan emphasizes, this 19th century
evolutionary theory of aging has been largely superceded
by another, developed by J.B.S. Haldane, Peter Medawar and
George C. Williams in the mid-20th century. According to the
predominant contemporary theory, aging is not an adaptation
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in any sense (Haldane, 1941; Medawar, 1952; Williams, 1957);
although not all biogerontologists adhere to this view (Longo
et al., 2005). That it did evolve reﬂects the fact that evolutionary
ﬁtness is ultimately a function of reproductive success, not of
individual long-term survival; and also pleiotropy, the capacity
of a gene mutation to aﬀect diﬀerent traits in diﬀerent cell
types and organs and at diﬀerent times. Because of pleiotropy,
genetic variants can appear in populations that cause changes
in early life that enhance reproductive success, but in later life
lead to increased pathology. But, critically, the disease and death
that such antagonistic pleiotropy causes in later life has little
eﬀect on evolutionary ﬁtness. This is because mortality in the
wild from extrinsic causes (e.g., from predation, starvation,
and disease) mean that few individuals survive long enough to
develop senescent pathologies (Williams, 1957). To be precise,
the pleiotropic eﬀects proposed by Williams (1957) may not
necessarily be antagonistic, in so far as the impact of late life
pathologies on ﬁtness may be negligible.
Thus, evolutionary theory tells us that aging is something
very much like a genetic disease: it is a set of pathologies
resulting from the action of pleiotropic gene mutations. Yet it
is not quite the same. Consider conventional genetic disease
mutations, such as those causing Duchenne muscular dystrophy
(DMD), aﬀecting the dystrophin gene. Suchmutations are wholly
deleterious, such that tackling DMD could involve correcting the
deﬁciency pharmacologically or with gene therapy. But in aging,
antagonistic pleiotropy means that the same genes that give us life
cause our death. For example, target of rapamycin (Tor), a strong
candidate for a gene that is subject to antagonistic pleiotropy,
promotes both development to adulthood, and the development
of many late-life pathologies (Blagosklonny, 2010). Yet as in a
conventional genetic disease, the option exists to correct the
deleterious eﬀects of such aging genes – but in later life, after the
early beneﬁcial eﬀects have been expressed. Consistent with this,
giving the Tor-inhibitory drug rapamycin to middle-aged mice
can extend their lifespan (Harrison et al., 2009).
Coming to Caplan’s other question: is aging distinguishable
from pathology? Given the similarity in meaning between
disease and pathology, asking this is similar to asking whether
aging is a disease. This also touches on another interesting
question, namely: in biological terms, what exactly constitutes
pathology? A full pathobiological account of a disease provides
an explanation of the origins and causes of disease and
illness in terms of biological malfunction. For diseases as
conventionally deﬁned, there is often a clear correspondence
between biological malfunction and disease; for example,
infection with the inﬂuenza virus can cause severe illness. But
biological malfunctions often occur that do not produce illness,
and so are not identiﬁed as pathology. For example, freckles are
caused by sun damage to melanocytes (I have freckles; a nurse
in Egypt once asked me: “Do they hurt?”); I also enjoy a glass of
whisky from time to time, which is a form of intoxicant. Some
senescent changes (e.g., skin wrinkling) fall into this category of
pathobiology without illness, this gray area between health and
sickness. The problem of precisely deﬁning terms such as disease
and pathology are the subject of much philosophical debate,
which lies beyond the scope of this essay.
An account of the biological mechanisms that cause aging
could help to answer the question of whether this process
is pathological: are its underlying causes recognizably a form
of biological deterioration, or something else? Here a snag
is that our understanding of the biology of aging remains
embryonic, though much progress has been made in recent
decades (Blagosklonny, 2008; Kenyon, 2010; Bartke et al., 2013;
Campisi, 2013; Vijg and Suh, 2013). The evolutionary theory of
aging implies that antagonistic pleiotropy is a cause of aging, but
does not identify the actual biological processes that antagonistic
pleiotropy aﬀects.
Numerous factors have been identiﬁed which play a
role in aging, such as cellular senescence, DNA damage
and inﬂammation, reviewed in (López-Otín et al., 2013).
Biogerontologists have also sought broader generalizations about
mechanisms of aging. For example, a long-standing theory is
that aging results from the accumulation of molecular damage
caused, for example, by reactive oxygen species (ROS) such
as the superoxide (O•−2 ) free radical (Harman, 1956; Sohal
and Weindruch, 1996; Kirkwood and Austad, 2000). According
to this view, cellular maintenance processes that protect
against damage also protect against aging. If molecular damage
causes aging then this implies a fundamentally pathological
process.
However, in recent years negative results of tests of the
ROS theory have raised doubts about how important molecular
damage is as a cause of aging; reviewed by (Van Raamsdonk
and Hekimi, 2010). This has led some to think outside of the
damage-maintenance box altogether and to consider alternative
paradigms (e.g., de Magalhães, 2012; Gladyshev, 2013). In
particular, it was proposed by Blagosklonny (2006, 2008) that the
primary cause of aging is not damage and loss of function, but
rather too high activity (or hyperfunction) of genes, and pathways
in later life. Blagosklonny’s (2006, 2008) ideas are strongly
rooted in Williams’s concept of antagonistic pleiotropy, but also
incorporate recent ﬁndings from experimental biogerontology,
e.g., studies of lifespan genetics, dietary restriction, and cellular
senescence. But like the earlier damage-maintenance paradigm
(and the concept of antagonistic pleiotropy), the hyperfunction
theory implies that aging is fundamentally a pathological
process.
As Caplan observes, the mechanisms proposed to cause aging
are similar to those known to underlie many disease processes.
He concludes that there is no clear distinction between aging
and pathology (Caplan, 1992, 2005), and this is supported
by accumulating evidence from biology. Having spent many
years studying aging in worms, the age changes one observes
involve accumulating pathology – nothing else. One way to
deﬁne aging (i.e., senescence) in biological terms is as the set
of pathologies that increase with advancing age; most of these
pathologies have endogenous origins, although they can be
strongly inﬂuenced by environmental factors, and many (but
not all) senescent pathologies can contribute to mortality (Gems,
2014); see also (Kulminski et al., 2007; Rockwood and Mitnitski,
2007). Consistent with this deﬁnition, treatments that extend
lifespan in animal models typically delay age-related pathology
and extend youth span: life extension only occurs as the result
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of prevention of pathology, whether the pathology is caused
by aging or by something else. Life extending treatments in
the laboratory invariably decelerate aging (rather than stopping
or reversing it); this results in a delay in the appearance of
age-related pathology (extending youthspan), but then such
pathologies still eventually appear, causing illness, and death.
With an understanding that aging is pathology, many of the
notions in the previous section lose validity. For example, the goal
of preventing diseases of aging without altering aging itself makes
little sense if aging itself is pathological, though it certainly makes
sense to prioritize action against the more lethal pathologies.
Also Kass’s creepy scenario of vigorous, healthy elderly people
fearfully facing imminent death appears highly improbable –
thankfully.
In a similar vein, the likelihood of recapitulating Tithonus’s
dreadful fate is very remote; in fact, to my knowledge no
biogerontologist has ever generated a worm or fruitﬂy Tithonus
in which life in a state of advanced senescence is greatly extended.
A more plausible concern is that geroprotective treatments that
increase lifespan could lead to expansion of morbidity (i.e., an
increase in the proportion of life spent in ill health due to
aging; Fries et al., 2011). This is possible, but assessment of the
worth of such treatments must also include the likely beneﬁts
in terms of expansion of the healthy period of life. Based on
animal model studies a plausible outcome of geroprotection is
a compression of lifetime morbidity in relative terms (i.e., as a
percentage of time alive), but not in absolute terms (i.e., years of
morbidity; Blagosklonny, 2012); this is described using a standard
representation in Figure 1.
Finally, the goal of enabling people to die without pathology,
or of pure aging, is untenable if non-pathological senescence does
not exist. In fact, the idea of elderly people dying of aging without
pathology is plainly nonsense, as noted previously (Blagosklonny,
2006); among the deﬁning properties of pathology, causing death
FIGURE 1 | Geroprotection is likely to reduce relative lifetime
morbidity. This represents the age increase in morbidity either without (A) or
with (B,C) life extension. After Fries et al. (2011), which suggests (B) as a likely
outcome of life extension. Model organism studies, and rejection of the
aging-disease dichotomy imply that (C) is more likely. Here the horizontal axis
represents time. In relative terms, (C) involves a compression of morbidity.
is surely a sine qua non. (Yet I recently discussed with a former
director of a major medical research funding agency the idea that
elderly people can die without pathology, and found that they
agreed with it).
It seems likely that advances in biogerontology will contribute
to geroprotective interventions which hold back the pathologies
of human aging; such interventions may well increase lifespan.
A recurrent feature of arguments against treating aging is an over-
emphasis on increased lifespan as an outcome, and neglect of
alleviation of illness. Thus, to say: “I would like a longer life” may
be presented as egoism or folly, but not “I would like to remain
free of cancer.” Likewise, one would not hold against someone
infected with, say, malaria their wish not to die from the disease –
and one would certainly not accuse them of egotism for wishing
to extend their life. The point here is that, in the end, senescence is
in many ways just like other severe diseases: it causes illness and
death, and treating it results in a longer life. Critics of treating
aging are often guilty of double standards, and of undervaluing
the well being – and life – of older people.
Biogerontological Utopianism and the
Definition of Geroprotection
Even among biogerontologists opinions diﬀer about whether
aging is a disease; for a recent argument against see (Rattan,
2014). But there is another idea about aging that is current
among biogerontologists that I believe impedes biogerontology
from beneﬁting medicine, which involves the notion of a central
process of aging.
A major point of reference for biogerontologists is the fact
that a number of interventions can cause large extensions in
both healthspan and lifespan in animal models (Kenyon, 2010;
Bartke et al., 2013). This is most striking in C. elegans, where
up to 10-fold increases in adult lifespan have been achieved
(Ayyadevara et al., 2008). One interpretation of such ﬁndings
is that there exists a central process of aging that causes all
age-related pathology. If one could intervene in this process in
humans one might achieve protection against the full spectrum of
age-related diseases (Holliday, 1996; Butler et al., 2008). Thus, an
aspiration of biogerontology has been to develop geroprotective
therapies that intervene in this central aging process – in aging
itself, thereby achieving great beneﬁts in terms of protection
against late-life disease.
This is a beautiful and inspiring prospect, yet one may
ﬁnd fault with it, in several respects. First, it relies on the
assumption that there exists such a central aging process. While
the damage-maintenance paradigm could imply that there is one,
the hyperfunction theory does not. The former suggests that
augmentation of somatic maintenance could slow the entire aging
process – even dramatically, leading to large increases in lifespan.
The disposable soma theory predicts that in terms of evolutionary
ﬁtness “the optimal level of investment in somatic maintenance
[. . .] is less than the level required for indeﬁnite survival,” i.e., that
increased somatic maintenance could prevent aging altogether
(Kirkwood and Rose, 1991). A further deduction drawn is that
aging may be reversible (de Grey et al., 2002).
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By contrast, the hyperfunction theory does not predict the
existence of a unitary, central aging process. Instead it suggests
that lifespan is limited by a set of pathologies caused by evolved
levels of activity of, for example, the Tor and insulin/IGF-1
signaling (IIS) pathways that are too high for optimal function
in later life (Blagosklonny, 2006, 2008). The fact that inhibition of
Tor/IIS increases lifespan does not signify that its over-activity
causes the entire aging process. That lifespan is not extended
indeﬁnitely by reducing Tor/IIS could reﬂect newly life-limiting
pathologies of diﬀerent etiologies (e.g., due to hyperfunction
in other pathways, or perhaps to stochastic molecular damage;
Blagosklonny, 2008).
This latter view is reconcilable with the declaration of eminent
medical researchers Peto and Doll (1997) that “There is no
such thing as aging,” meaning that there is no single process
underlying aging. One possible hypothesis about senescence
is that it is a collection of individual pathologies, each
which has its own time-dependent, cumulative etiology, e.g.,
mutation accumulation for cancer, β-amyloid aggregation for
Alzheimer’s disease and so on. If this were correct, it would
make little sense to study aging overall. However, Peto and
Doll also opine that “some [age-related phenomena] will
probably have part or all of their mechanisms of origin in
common, but some may not.” Critically, the discovery of
the eﬀects on late-life health and lifespan of Tor/IIS and
other pathways demonstrates that more aging pathologies have
common mechanisms than had previously been supposed; for
a diagrammatic representation of this, see Figure 2. But this
does not mean that Tor/IIS controls the aging process, that
causes all diseases of aging. An argument against the utility
of the individual pathologies view (Figure 2) is that treatment
of one age-related pathology can sometimes exacerbate another
(Barzilai, 2014).
The second issue is that such utopianism neglects a
lesson from biogerontology of particular utility in terms of
achieving improvements in late life health: the eﬃcacy of
preventative approaches to decelerate the development of age-
related pathologies. This is as true of interventions that prevent
many pathologies and considerably extend lifespan (as in the
eﬀects of dietary restriction on rodents) as of interventions that
suppress a smaller number of, or individual pathologies.
The question of how to deﬁne anti-aging (or geroprotective)
treatments is an open one, and I have discussed it more fully
elsewhere (Gems, 2014). Arguably, it is both more realistic and
FIGURE 2 | Aging as a cause of age-related disease: different models.
(A,B), derived from Peto and Doll (1997). (A) There is no aging process, only
individual diseases of aging. (B) A few diseases of aging may have shared
mechanisms, (C) A central aging process causes diseases of aging; the utopian
view. (D) Mixed model, based on recent findings and concepts. Some pathways
(e.g., target of rapamycin/insulin/IGF-1 signaling, Tor/IIS) promote many
pathologies, including a number that limit healthspan and lifespan. But this does
not mean that Tor/IIS controls the aging process, only part of it.
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more useful to employ the broader deﬁnition of geroprotection,
that includes protection against multiple or single pathologies of
aging. Eﬀective deployment of narrow-spectrum geroprotectants
is something that is more achievable in the short term, and
would help to establish a practice and tradition of geroprotection
that could over time be extended to the use of broader
spectrum geroprotectants. As deﬁned, some eﬀective narrow-
spectrum geroprotectants already exist. One example is the
regular use of sun-block to prevent the slow accumulation
of solar damage to the skin. Another, that is currently being
tested, is the use of the cardiovascular polypill to reduce risk
of cardiovascular disease (Wald and Law, 2003). I suspect that
the more utopian deﬁnition of geroprotection, though inspiring
to biogerontologists, is a turn-oﬀ for clinicians, who view it as
unrealistic.
Conclusion
To act ethically a realistic grasp of relevant facts is critical. This
is particularly important for aging, the main cause of chronic
disease and death in the world today. Yet traditional ideas about
aging include some major misconceptions, including the aging-
disease false dichotomy. It is to be hoped that such ideas do
not misguide those responsible for the healthcare interests of
older people, including those responsible for setting medical
research priorities. Neglect resulting from misunderstanding
aging may cause harm by allowing preventable illness, both
now and in the future – given that geroprotection is most
eﬃcacious in the form of prevention. To achieve the best
outcomes in terms of the future health of older people, it
is vital to adopt a frank and rational attitude to aging. We
must draw aside the rosy veil of tradition and face aging
for what it is, and in all its horror: the greatest disease of
them all.
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